New hope for advanced liver cancer: AK112 combo trial launches

NCT ID NCT06530251

Recruiting now Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called AK112, alone or with other treatments, for people with advanced liver cancer that hasn't responded to standard care. The first part checks safety and the right dose, while the second part compares the new combinations to existing therapies. About 280 adults with liver cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)
RECRUITING

Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.